NEUROCRINE BIOSCIENCES INC 8-K

What Happened

• Neurocrine Biosciences, Inc. (NBIX) filed an 8-K reporting the closing of a merger (press release issued May 18, 2026) and that on May 14, 2026 it entered into a five‑year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank, N.A. as administrative and collateral agent. The company made an initial borrowing of $600.0 million on the closing date.

Key Details

• Facility size & term: $1.0 billion senior secured revolving credit facility, five‑year maturity.
• Initial draw: $600.0 million borrowed on May 14, 2026.
• Interest & fees: Variable rates — either Term SOFR + 1.125% to 1.75% or alternate base rate + 0.125% to 0.75%, plus customary agency and a commitment fee of 0.10%–0.25% on unused capacity.
• Security & guarantees: Company granted a security interest in substantially all assets; material domestic subsidiaries must guarantee and grant security interests (customary exceptions apply).
• Financial covenants: Quarterly tests including max total net leverage ratio 3.75:1.00 (can increase to 4.25:1.00 in certain post‑acquisition periods at the company’s election) and minimum consolidated interest coverage ratio of 2.00:1.00.

Why It Matters

• The new $1.0B facility and the $600M initial draw materially increase Neurocrine’s liquidity and provide funding flexibility following the merger close. Because the facility is secured and includes leverage and interest‑coverage covenants tested quarterly, investors should watch the company’s consolidated leverage and coverage metrics each quarter to assess covenant compliance risk. The filing also notes that financial statements for the acquired business will be provided later; those filings will be important for understanding the combined company’s financial position.